Translating Discoveries of Glial Biology & Peripheral Immune Pathways into Novel Approaches to Target Neuroinflammation Across the Neurodegenerative Disease Spectrum
Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil’s TREM2 asset, Ventus’ NLRP3 inhibitor in phase 2a, and promising phase 3 BTKi readouts from Sanofi and Roche, the field is beginning to show encouraging signs of clinical viability in targeting neuroinflammation. Now the real race begins. Uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today’s successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease.
The 8th Neuroimmunology Drug Development Summit is the industry’s only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year’s expanded program goes deeper than ever into emerging glial biology (TREM2 & beyond), peripheral immune pathways, and the technologies redefining how we discover, validate, and measure neuroinflammatory targets.
Across three days, 80+ discovery, preclinical, and translational leaders from Biogen, Sanofi, Merck, Lundbeck, Vigil Neuroscience, Bristol Myers Squibbs and more will unite to share hyper-current insights on merging neuroinflammatory mechanisms, cutting-edge glial models and omics technologies accelerating target discovery, next-generation biomarkers enhancing translation, and early clinical signals from novel neuroimmune-targeting therapies.
Join the global neuroimmunology community this year and help define the future of immune-modulating therapies for the brain.
Excellent organization, choice of the topics and corresponding industry experts and high level discussions on the science, drug discovery and development.
Executive Director & Head of Inflammation and Neuroscience Research, Novo Nordisk
The Neuroimmunology Drug Development Summit provided an engaging experience with the experts in the field. I appreciated the opportunity to network with scientists across academic and industry and learn about their challenges.
Senior Scientist, Pfizer
I enjoyed the event particularly the chance to connect with a diverse group of attendees. The pre-conference workshop and presentations were of great quality, and the audience was interactive throughout. The small group roundtables fostered meaningful discussions.
Senior Director & Senior Principal Scientist, Merck
Explore the Full Event Guide
- 80+ discovery, preclinical & translational neuroimmunology experts from leading biopharma and academia
- 3 days of cutting-edge insights across neuroinflammatory targets, glial biology, biomarkers & translational innovation
- Deep-dive agenda strand: Bridging Peripheral & Central Immunity, exploring next-generation B & T cell targets enabling earlier, more precise CNS intervention
- Hear from 25+ top speakers from Sanofi, Biogen, Merck, AbbVie, BMS, Lundbeck, Vigil Neuroscience and more
- Unmissable debates on humanized models, emerging insights into inflammation-driven psychosis mechanisms, and early clinical signals from novel neuroimmune-targeting therapies
Speakers
Sorry, we couldn't find any posts. Please try a different search.
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover cutting-edge sessions on neuroinflammatory mechanisms, glial biology, peripheral immune targets, and translational biomarkers redefining CNS drug development.
Partner With Us
Connect with senior discovery, preclinical, and translational neuroscientists seeking innovative targets, models, and omics solutions to advance neuroimmunology pipelines.
Join Biopharma Experts
Network with industry pioneers shaping the next generation of immune-modulating therapies for neuroinflammatory and neuroimmune disorders.